Correspondence: The First Biosimilar for Biologics in Allergy: <scp>CT</scp> ‐ <scp>P39</scp> (Omlyclo‐Omalizumab‐Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps

Klimek, L;Mullol, J;Reitsma, S;Van Gerven, L;Ollert, M;et.al.
(2026) Allergy — Vol. 0, p. 1-3 (2026)

Files

Correspondence The First Biosimilar for Biologics in Allergy CT_E2_80_90P39 Omlyclo_E2_80_90Omalizumab_E2_80_90Igec .pdf
  • Open Access
  • Adobe PDF
  • 357.37 KB
Download

Details

Authors
  • Klimek, Lorcid-logoCenter for Rhinology and Allergology Wiesbaden Germany
    Author
  • Mullol, Jorcid-logoRhinology Unit and Smell Clinic, ENT Department, Hospital Clínic Barcelona, IDIBAPS Universitat de Barcelona, CIBERES Barcelona Spain
    Author
  • Reitsma, Sorcid-logoAmsterdam Rhinology Team (ART), Department of Otorhinolaryngology and Head and Neck Surgery Amsterdam University Medical Center, University of Amsterdam Amsterdam the Netherlands
    Author
  • Van Gerven, Lorcid-logoDepartment of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven Leuven Belgium
    Author
  • Ollert, Morcid-logoDepartment of Infection and Immunity Luxembourg Institute of Health (LIH) Esch‐sur‐Alzette Luxembourg
    Author
  • et. al.
Show more
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Klimek, L., Mullol, J., Reitsma, S., Van Gerven, L., Maza‐solano, J., Lundberg, M., Becker, S., Bärhold, F., Gawlik, R., Sokolowska, M., Hagemann, J., Akdis, C., Hox, V., Toppila‐salmi, S., Adcock, I., Escribese, G., Palomares, O., Moreira, A., Bonadonna, P., et al. (2026). Correspondence: The First Biosimilar for Biologics in Allergy: <scp>CT</scp> ‐ <scp>P39</scp> (Omlyclo‐Omalizumab‐Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps. Allergy, 0, 1-3. https://doi.org/10.1111/all.70366 (Original work published 2026)